Panavance Therapeutics
Our Science
Pipeline
About GP-2250
About
About Panavance
Leadership
Board of Directors
Advisors & Collaborators
Contact Panavance
Resources
Publications
Brochures
Videos
Press Releases
Events
Participate
Let’s engage
.
Mechanisms and rational combinations with GP-2250, novel oxathiazine derivative in ovarian cancer.
August 7, 2024
/
0 Minute Read